Rare Combined Small Cell Lung Carcinoma and Lung Squamous Cell Carcinoma Response to PD-1 Inhibitor as Third-Line Therapy: A Case Report.

This case provides a meaningful reference for the third-line treatment of SCLC combined LUCS patients. This case also provides valuable information on the response to PD-1 inhibition of patients with c-SCLC based on TMB-H and better understanding of PD-1 therapy applications in the future.